Next Article in Journal
Application of the Chinese Version of the Montreal Cognitive Assessment-Basic for Assessing Mild Cognitive Impairment in Parkinson’s Disease
Previous Article in Journal
Increased Serum Prolactin and Excessive Daytime Sleepiness: An Attempt of Proof-of-Concept Study
Systematic Review

The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies

Royal Derby Hospital Centre, School of Medicine, University of Nottingham, Derby DE22 3DT, UK
*
Author to whom correspondence should be addressed.
Academic Editors: Omar Cauli, Pilar Pérez-Ros and Vanessa Ibáñez-del Valle
Brain Sci. 2021, 11(12), 1573; https://doi.org/10.3390/brainsci11121573
Received: 27 October 2021 / Revised: 23 November 2021 / Accepted: 24 November 2021 / Published: 28 November 2021
(This article belongs to the Topic Mechanisms and Treatments of Neurodegenerative Diseases)
Currently, there are no pharmacological treatments able to reverse nigral degeneration in Parkinson’s disease (PD), hence the unmet need for the provision of neuroprotective agents. Cannabis-derived phytocannabinoids (CDCs) and resveratrol (RSV) may be useful neuroprotective agents for PD due to their anti-oxidative and anti-inflammatory properties. To evaluate this, we undertook a systematic review of the scientific literature to assess the neuroprotective effects of CDCs and RSV treatments in pre-clinical in vivo animal models of PD. The literature databases MEDLINE, EMBASE, PsychINFO, PubMed, and Web of Science core collection were systematically searched to cover relevant studies. A total of 1034 publications were analyzed, of which 18 met the eligibility criteria for this review. Collectively, the majority of PD rodent studies demonstrated that treatment with CDCs or RSV produced a significant improvement in motor function and mitigated the loss of dopaminergic neurons. Biochemical analysis of rodent brain tissue suggested that neuroprotection was mediated by anti-oxidative, anti-inflammatory, and anti-apoptotic mechanisms. This review highlights the neuroprotective potential of CDCs and RSV for in vivo models of PD and therefore suggests their potential translation to human clinical trials to either ameliorate PD progression and/or be implemented as a prophylactic means to reduce the risk of development of PD. View Full-Text
Keywords: cannabinoids; cannabis-derived phytocannabinoids; neuroprotection; resveratrol; Parkinson’s disease cannabinoids; cannabis-derived phytocannabinoids; neuroprotection; resveratrol; Parkinson’s disease
Show Figures

Figure 1

MDPI and ACS Style

Prakash, S.; Carter, W.G. The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies. Brain Sci. 2021, 11, 1573. https://doi.org/10.3390/brainsci11121573

AMA Style

Prakash S, Carter WG. The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies. Brain Sciences. 2021; 11(12):1573. https://doi.org/10.3390/brainsci11121573

Chicago/Turabian Style

Prakash, Samay, and Wayne G. Carter. 2021. "The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies" Brain Sciences 11, no. 12: 1573. https://doi.org/10.3390/brainsci11121573

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop